Skip to content
Search

Latest Stories

Brain study reveals promising new approach to treating depression

The discovery could potentially accelerate the development of faster-acting medications for mood disorders such as major depression and anxiety, which can be difficult to treat

Brain study reveals promising new approach to treating depression

Researchers at the Wertheim UF Scripps Institute for Biomedical Innovation & Technology in the US have found that the inhibitory effect of glycine, a commonly occurring amino acid in the brain, could be a promising new therapeutic target for mood disorders such as major depression and anxiety.

This discovery could potentially accelerate the development of faster-acting medications for these conditions, which can be difficult to treat.


In a recent study published in the journal Science, the scientists explained that answering the question of how sensors on brain cells receive and transmit signals is key to understanding various processes such as vision, pain, memory, and behaviour.

"It's amazing how basic science goes. Fifteen years ago, we discovered a binding partner for proteins we were interested in, which led us to this new receptor," said Kirill Martemyanov, corresponding author of the study.

In 2018, the researchers discovered that mice lacking the GPR158 gene exhibited resilience to chronic stress, providing strong evidence that GPR158 could serve as a therapeutic target. However, the question of what sent the signal remained unanswered.

In 2021, the team solved the structure of GPR158 and found that the receptor resembled a microscopic clamp with a compartment, similar to something found in bacteria rather than human cells.

"We were barking up the completely wrong tree before we saw the structure," said Martemyanov, who chairs the neuroscience department at the institute.

"We said, 'Wow, that's an amino acid receptor. There are only 20, so we screened them right away and only one fit perfectly. That was it. It was glycine," he said.

Additionally, the team discovered that the signalling molecule associated with GPR158 was not an activator, but rather an inhibitor in the cells.

In other words, the researchers explained that the active part of GPR158 was connected to a partnering molecule that slowed down cellular activity, rather than speeding it up, when glycine was bound to it.

According to Thibaut Laboute, the first author of the study, G protein Coupled Receptors, such as GPR158, typically bind G proteins. However, in this case, the receptor was binding to an RGS protein, which has the opposite effect of activation.

Glycine is marketed as a nutritional supplement with claims of improving mood. As a fundamental component of proteins, glycine impacts various cell types, often in intricate ways. But while it can transmit inhibitory signals in certain cells, it can also convey excitatory signals in others. Martemyanov noted that there is a pressing need for new and improved medication options.

(With inputs from PTI)

More For You

Mounjaro price rise

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro

iStock

Mounjaro’s highest dose to rise from £122 to £247.50, not £330

Highlights:

  • Eli Lilly had announced a steep price rise of up to 170% for Mounjaro.
  • A new discount deal with UK suppliers will limit the increase for patients.
  • Pharmacies will still apply a mark-up, but consumer costs are expected to rise less than initially feared.
  • NHS pricing remains unaffected due to separate arrangements.

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro, easing fears of a sharp rise in costs for UK patients. The new arrangement means that, from September, pharmacies and private services will face smaller wholesale increases than first expected, limiting the impact on consumers.

Why the price rise was announced

Earlier this month, Eli Lilly said it would raise Mounjaro’s list price by as much as 170%, which could have pushed the highest monthly dose from £122 to £330. The company argued that UK pricing needed to align more closely with higher costs in Europe and the United States.

Keep ReadingShow less
chicken-pox-istock

The Department of Health said the rollout would reduce missed days at nursery and school, cut time parents take off work, and save the NHS about £15 million a year. (Representational image: iStock)

iStock

England to introduce free chickenpox vaccine for children from 2026

CHILDREN in England will be offered a free chickenpox vaccine for the first time from January 2026, the government has announced.

GP practices will give eligible children a combined vaccine for measles, mumps, rubella and varicella (MMRV) as part of the routine childhood vaccination schedule. Around half a million children each year are expected to be protected.

Keep ReadingShow less
Naga Munchetty urges women to prioritise their health

Naga Munchetty

Naga Munchetty urges women to prioritise their health

WHEN broadcaster and journalist Naga Munchetty began speaking openly about her experiences with adenomyosis and debilitating menstrual pain, the response was overwhelming.

Emails and messages poured in from women who had endured years of dismissal, silence and shame when it came to their health. That outpouring became the driving force behind her new book, It’s Probably Nothing, which calls for women to be heard and to advocate for themselves in a medical system that has too often ignored them.

Keep ReadingShow less
London temple project for Shree Banke Bihari launched

London temple project for Shree Banke Bihari launched

Mahesh Liloriya

The Shree Kunj Bihari Vrindavan (UK) Temple has officially launched its project to establish a grand home for Shree Banke Bihari in London.

The inaugural event, held in Harrow from 4 pm, featured devotional chants, the Deep Pragtya ceremony, and a presentation outlining the temple’s vision. Speaking at the gathering, Shalini Bhargava described the planned temple as “a spiritual home promoting bhakti, unity and seva for generations to come.”

Keep ReadingShow less
Dickie and Watt

Dickie and Watt launched BrewDog at the age of 24

Getty Images

BrewDog co-founder Martin Dickie leaves after 17 years as James Watt steps back

Highlights:

  • Martin Dickie has announced his departure from BrewDog and the alcohol industry.
  • He co-founded the Ellon-based brewer with James Watt in 2007.
  • Dickie cited family time and personal reasons for his exit.
  • His departure follows recent bar closures as part of a company restructuring.
  • BrewDog confirmed no further leadership changes will follow.

BrewDog co-founder Martin Dickie has announced he is leaving the Scottish brewer and the wider alcohol industry for “personal reasons.” Dickie, who founded the Ellon-based business with James Watt in 2007, said he wanted to spend more time with his family after more than two decades in brewing and distilling.

Early beginnings

Dickie and Watt launched BrewDog at the age of 24, starting from a garage in Fraserburgh and selling hand-filled bottles from a van at local markets. The company grew rapidly to become one of the UK’s best-known craft brewers.

Keep ReadingShow less